
In a First, FDA Permits Marketing of E-Cigarette Products in the US

WASHINGTON — The Food and Drug Administration late Tuesday authorized the marketing of an electronic cigarette in the United States. A groundbreaking development in a long running debate over the healthfulness of such products.
Specifically, the FDA granted the R.J. Reynolds Vapor Company the right to sell its Vuse Solo closed ENDS device as well as the tobacco-flavored e-liquid pods that are used with it.
In a press release announcing the decision, the agency said study participants who used only the approved products were exposed to fewer harmful and potentially harmful constituents from aerosols compared to users of combusted cigarettes.
The FDA also said it determined the potential benefit to smokers who switch completely or significantly reduce their cigarette use outweighed the risk to youth so long as R.J. Reynolds adhered to specific requirements related to reducing youth exposure and access to the products.
“Today’s authorizations are an important step toward ensuring all new tobacco products undergo the FDA’s robust, scientific premarket evaluation,” said Mitch Zeller,, director of the FDA’s Center for Tobacco Products, in a written statement.
“The manufacturer’s data demonstrates its tobacco-flavored products could benefit addicted adult smokers who switch to these products – either completely or with a significant reduction in cigarette consumption – by reducing their exposure to harmful chemicals,” Zeller said.
“We must remain vigilant with this authorization and we will monitor the marketing of the products, including whether the company fails to comply with any regulatory requirements or if credible evidence emerges of significant use by individuals who did not previously use a tobacco product, including youth. We will take action as appropriate, including withdrawing the authorization,” he said.
Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.
In The News
Health
Voting
Business
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during... Read More
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during a Senate hearing Wednesday by saying his company is preparing for a sharp decline in demand. With as much as a 90% drop in customers as... Read More
WASHINGTON — Given increased economic stress around the world, the official release of a new report by the Wilson Center’s... Read More
WASHINGTON — Given increased economic stress around the world, the official release of a new report by the Wilson Center’s Middle East Program on female entrepreneurship in the MENA region may be that much more relevant. The Middle East and North Africa region has one of... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia,... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia, Karuna Therapeutics announced Monday that it is on track to submit KarXT to the Food and Drug Administration for approval by summer. If that comes to... Read More
COLUMBUS, Ohio — The state of Ohio filed a 58-count civil lawsuit against Norfolk Southern Tuesday, seeking to hold the... Read More
COLUMBUS, Ohio — The state of Ohio filed a 58-count civil lawsuit against Norfolk Southern Tuesday, seeking to hold the Class 1 railroad financially responsible for the Feb. 3 derailment in East Palestine that caused the release of an estimated 1 million gallons of hazardous chemicals.... Read More
WASHINGTON — Saudi Arabia’s nearly $37 billion purchase of new Boeing passenger jets is yet another sign of the United... Read More
WASHINGTON — Saudi Arabia’s nearly $37 billion purchase of new Boeing passenger jets is yet another sign of the United States' rebirth as a global manufacturing leader, Biden administration officials declared Tuesday. Their enthusiastic assessment came just moments after Boeing announced that Saudi Arabia’s sovereign-wealth fund,... Read More
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this... Read More
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly. The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They... Read More